Can levosimendan reduce ECMO weaning failure in cardiogenic shock?: a cohort study with propensity score analysis
- Resource Type
- article
- Authors
- Enrique Guilherme; Matthias Jacquet-Lagrèze; Matteo Pozzi; Felix Achana; Xavier Armoiry; Jean-Luc Fellahi
- Source
- Critical Care, Vol 24, Iss 1, Pp 1-9 (2020)
- Subject
- Levosimendan
VA-ECMO
Cardiogenic shock
ECMO weaning failure
Circulatory failure
Medical emergencies. Critical care. Intensive care. First aid
RC86-88.9
- Language
- English
- ISSN
- 1364-8535
Abstract Background Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has been increasingly used over the last decade in patients with refractory cardiogenic shock. ECMO weaning can, however, be challenging and lead to circulatory failure and death. Recent data suggest a potential benefit of levosimendan for ECMO weaning. We sought to further investigate whether the use of levosimendan could decrease the rate of ECMO weaning failure in adult patients with refractory cardiogenic shock. Methods We performed an observational single-center cohort study. All patients undergoing VA-ECMO from January 2012 to December 2018 were eligible and divided into two groups: group levosimendan and group control (without levosimendan). The primary endpoint was VA-ECMO weaning failure defined as death during VA-ECMO treatment or within 24 h after VA-ECMO removal. Secondary outcomes were mortality at day 28 and at 6 months. The two groups were compared after propensity score matching. P